Abstract
Medroxyprogesterone acetate was administered to six patients with the polycystic ovary syndrome. The drug resulted in a significant reduction in serum LH, plasma concentration and plasma production rate of testosterone in each patient. In addition, five of the six patients showed a significant increase in the metabolic clearance rate of testosterone. This study also confirms previous findings by others of an increase in serum LH in the syndrome.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call